6 news items
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
GLPG
14 Jun 24
presentation includes updated safety and efficacy data for GLPG5101 in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal
Galapagos And Adaptimmune Enter Clinical Collaboration To License Next-Generation TCR T-Cell Therapy For Cancer Using Decentralized Manufacturing Platform
ADAP
GLPG
30 May 24
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4
Galapagos reports first quarter 2024 financial results
GLPG
2 May 24
candidates due to safety or efficacy concerns or other reasons), risks related to the acquisitions of CellPoint and AboundBio, including the risk that we may
rvc7vtds4kao2mg0n4ysy1ro168acaitqa2ow
GLPG
4 Apr 24
-label, multi-center studies designed to assess the safety, efficacy and feasibility of point-of-care manufactured GLPG5101 and GLPG5201 in patients
- Prev
- 1
- Next